非小细胞肺癌组织PTPRJ的水平及其临床意义

Expression and clinical significance of PTPRJ in non-small cell lung cancer tissues

目的探讨非小细胞肺癌(NSCLC)组织中蛋白酪氨酸磷酸酶受体J(PTPRJ)的水平及临床意义。方法收集本院2015年1月至2017年12月手术切除的NSCLC患者癌组织112例,采用实时定量PCR(QPCR)以104例癌旁组织为对照检测癌组织的PTPRJ mRNA水平,根据癌组织PTPRJ mRNA水平的均数分为低表达组(<均数)和高表达组(≥均数),分析不同临床病理特征(性别、年龄、吸烟史、肿瘤大小、淋巴结转移、TNM分期、病理类型和PS评分)对应癌组织的PTPRJ mRNA水平和表达分布情况,根据随访资料比较不同PTPRJ mRNA水平的中位总生存期(OS)。结果 QPCR结果显示NSCLC组织的PTPRJ mRNA水平为0. 313±0. 149,低于癌旁组织的1. 028±0. 286,差异有统计学意义(P<0. 05)。将112例NSCLC组织分为低表达60例和高表达52例; PTPRJ mRNA水平与NSCLC的性别、年龄、病理类型和PS评分均无关,而与吸烟史、淋巴结转移、肿瘤大小和TNM分期有关。有吸烟史、淋巴结转移、肿瘤较大(≥3 cm)和分期较晚(Ⅲ期)的PTPRJ mRNA水平和高表达率分别为0. 290±0. 128和38. 0%(30/79)、0. 282±0. 158和28. 6%(20/70)、0. 244±0. 099和26. 2%(17/65)及0. 266±0. 106和29. 7%(11/37),均低于无吸烟史、淋巴结无转移、肿瘤较小(<3 cm)和分期较早(Ⅰ～Ⅱ期)的0. 367±0. 182和66. 7%(22/33)、0. 364±0. 119和76. 2%(32/42)、0. 407±0. 156和74. 5%(35/47)及0. 336±0. 162和54. 7%(41/75)。全组随访时间9～36个月,中位随访25个月,中位OS为34. 0个月,其中PTPRJ mRNA高表达者的中位OS超过36. 0个月,长于低表达者的24. 0个月,差异有统计学意义(P<0. 05)。结论低表达的PTPRJ参与了NSCLC的发生发展,发挥类似抑癌基因的作用且低表达者的预后较差,该因子有望成为诊断和判断NSCLC预后的潜在因子。

Objective To explore the expression level and clinical significance of protein tyrosine phosphatase receptor type J( PTPRJ) in non-small cell lung cancer( NSCLC) tissues. Methods One hundred and twelve cases of NSCLC tissues were collected from January 2014 to December 2017. PTPRJ gene was detected by real-time quantitative polymerase chain reaction( QPCR) in NSCLC tissues with 104 cases of paracancerous tissues as control. According to the average value of PTPRJ mRNA level in cancer tissues,NSCLC patients were divided into low-expression group( <average value) and high-expression group( ≥average value). The expression and distribution of PTPRJ in different clinicopathological features( sex,age,smoking history,tumor size,lymph node metastasis,TNM stage,pathological type and PS score) were analyzed. The median overall survival( OS) of different PTPRJ mRNA levels was compared according to follow-up data. Results The mRNA level of PTPRJ in NSCLC tissues was 0. 313 ± 0. 149,lower than1. 028±0. 286 in adjacent tissues( P<0. 05). According to the average value of PTPRJ mRNA,112 NSCLC tissues was divided into 60 cases with low-expression and 52 cases with high-expression. The results showed that PTPRJ mRNA level was dependent with gender,age,pathological type and PS score of NSCLC,but associated with smoking history,lymph node metastasis,tumor size and TNM stage. The levels and high-expression rates of PTPRJ in patients with smoking history,lymph node metastasis,large tumor size( > 3cm) and late stages( stage Ⅲ) were 0. 290± 0. 128 and 38. 0%( 30/79),0. 282± 0. 158 and 28. 6%( 20/70),0. 244± 0. 099 and26. 2%( 17/65),0. 266±0. 106 and 29. 7%( 11/37),higher than 0. 367±0. 182 and 66. 7%( 22/33),0. 364±0. 119 and 76. 2%( 32/42),0. 407±0. 156 and 74. 5%( 35/47) and 0. 336± 0. 162 and 54. 7%( 41/75) of patients with without smoking history,lymph node metastasis,small tumor size( < 3 cm) and early stage( Ⅰ-Ⅱ). The follow-up time was 9-36 months( median 25. 0months) and the median OS was 34. 0 months. The median OS of PTPRJ high-expression was more than 36. 0 months,longer than24. 0 months of low-expression( P<0. 05). Conclusion Low expression of PTPRJ participates in the occurrence and development of NSCLC and plays a role of tumor suppressor gene. The prognosis of low expression of PTPRJ is poor. This factor is expected to become a potential factor in the diagnosis and predicting of the prognosis of NSCLC.